Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Corporativo Fragua, S.A.B. de C.V. (FRAGUAB.MX)
Guadalajara, JA, MX
Corporativo Fragua, S.A.B. de C.V. oversees a chain of Superfarmacia drugstores located throughout Mexico. These retail outlets provide a wide array of products, including medicines, perfumes, photography supplies, household goods, and diverse food items such as fresh produce, baked goods, and deli meats. Furthermore, the company engages in the processing and sale of photographic apparatus and offers freight services. Established in 1942, Corporativo Fragua, S.A.B. de C.V. has its main office situated in Guadalajara, Mexico.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.61% | -1.02% | -6.19% | -8.31% | -12.53% | -12.61% | -2.22% | -6.73% | +51.56% | +121.48% | +3,364.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+9.9% ★ Q1'26: +7.1% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-4.0% Q1'26: -7.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+2.9% ★ Q1'26: +1.8% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+6.2% Q1'26: +6.9% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+20.6% ★ Q1'26: +20.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.48× ★ Q1'26: 0.38× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
97.92B
est: 97.53B (+0.4%)
|
109.37B
est: 109.96B (-0.5%)
|
120.24B
est: 121.98B (-1.4%)
|
132.12B
est: 132.30B (-0.1%)
|
144.66B
144.66B – 144.66B
+9.3% YoY
|
157.72B
157.72B – 157.72B
+9.0% YoY
|
| EBITDA |
6.70B
est: 5.94B (+12.8%)
|
5.63B
est: 6.70B (-15.9%)
|
6.39B
est: 7.54B (-15.3%)
|
8.82B
est: 8.18B (+7.8%)
|
8.94B
8.94B – 8.94B
+9.3% YoY
|
9.75B
9.75B – 9.75B
+9.0% YoY
|
| EBIT |
6.31B
est: 5.20B (+21.4%)
|
5.19B
est: 5.87B (-11.5%)
|
4.85B
est: 6.74B (-28.0%)
|
8.24B
est: 7.31B (+12.7%)
|
7.99B
7.99B – 7.99B
+9.3% YoY
|
8.71B
8.71B – 8.71B
+9.0% YoY
|
| Net Income |
3.18B
|
4.50B
est: 3.98B (+13.0%)
|
4.90B
est: 4.07B (+20.3%)
|
4.69B
est: 4.86B (-3.5%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
17.17B
est: 17.57B (-2.3%)
|
19.82B
est: 19.81B (+0.1%)
|
23.29B
est: 22.56B (+3.3%)
|
26.45B
est: 24.47B (+8.1%)
|
26.75B
26.75B – 26.75B
+9.3% YoY
|
29.17B
29.17B – 29.17B
+9.0% YoY
|
| EPS |
30.98
|
43.87
est: 38.81 (+13.0%)
|
47.60
est: 39.71 (+19.9%)
|
45.68
est: 47.32 (-3.5%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Dividend Growth ETF IGRO | 0.03% | 394.0K | 0.15% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 34.0K | 0.44% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 1.1K | 0.56% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 11.9K | 0.28% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 6.4K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adriana Arvizu Requena | Investor Relations Manager | — | — |
| Brenda Silva Rubio | Legal Director & Secretary | — | — |
| Guillermina Arroyo Chavez | Vice President of Board of Directors & Director of Personnel Development | — | — |
| Irene Belloso Villalvazo | General Accountant | — | — |
| Ivan Acuna Regato | Director of Operations | — | — |
| Javier Arroyo Chavez | Executive President of Board of Directors | — | — |
| Javier Arroyo Navarro | Director General | — | — |
| José Antonio Jiménez García | Corporate Treasury Manager | — | — |
| Margarita Paloma Farías Gonzalez | Director of Human Resources | — | — |
| María Fernanda García Orozco | Finance Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FRAGUAB.MX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
